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We present a rare case of acquired von Willebrand syndrome (AVWS) caused by a mantle cell lymphoma. A 61-year-old male
su3ered from recurrent bleeding symptoms since a fewmonths. Initially, physical examination was normal. vonWillebrand factor
antigen (VWF:Ag) level and factor VIII activity (FVIII:C) were low (0.31 IU/ml and 0.43 IU/ml, resp.). Ristocetin cofactor activity
(VWF:RCo) was 0.09 IU/ml, and collagen binding activity (VWF:CB) was 0.10 IU/ml. VWF:RCo/VWF:Ag ratio was 0.29, and
RIPA value was normal. Highest molecular weight VWF multimers were absent. A diagnosis of von Willebrand Disease (VWD)
type 2A was made. However, no genetic mutation was found. No inhibitory antibodies against VWF or factor VIII were detected.
A few months later, cervical, axillary, and inguinal lymphadenopathy was found on physical examination. A CT scan conArmed
multiple enlarged lymph nodes, and a clonal B-cell population matching a mantle cell lymphoma was detected in the bone
marrow. Chemoimmunotherapy resulted in a very good partial remission and concomitantly in a rapid decrease of bleeding
problems and complete normalization of FVIII:C and VWF:Ag. 'e diagnosis of AVWS cannot be rejected by negative mixing
studies due to diDculties in the detection of autoantibodies and because of a highly heterogeneous pathogenesis of AVWS. When
the suspicion of AVWS is high, an extensive investigation should be performed to And the underlying cause.
1. Introduction
Acquired vonWillebrand syndrome (AVWS) is a rare bleeding
disorder, associated with a variety of underlying medical
conditions. Due to similar clinical and laboratory mani-
festations, di3erentiation of congenital and acquired von
Willebrand Disease (VWD) can be challenging. A nega-
tive family history and onset of bleeding symptoms later
in life make an AVWS more likely than a congenital VWD
[1]. When the suspicion of AVWS is high, a search for the
underlying cause should be initiated. We present a rare
case of AVWS associated with a mantle cell lymphoma.
2. Case Presentation
A 61-year-old man was referred to our department for
evaluation of a hemorrhagic diathesis. He su3ered from
recurrent epistaxis, hematuria, spontaneous hematomas,
and rectal bleeding since a few months. In 2003, he expe-
rienced a massive bleeding after a transurethral resection of
the prostate due to surgical reasons. In the following years,
he underwent multiple surgical procedures without bleeding
complications. Family history was negative for bleeding dis-
orders, although his father died from an intestinal bleeding
without a previous history of bleeding diathesis. Besides a few
hematomas on his arms and hands, physical examination was
normal. Laboratory studies showed a normal platelet count
(255×109/l, reference range 150–400×109/l), a normal pro-
thrombin time of 13 seconds (INR 1.0), and a slightly
lengthened activated partial thromboplastin time (APTT)
of 35 seconds (reference range 26–34 seconds). Closure times
obtained by the PFA-100 (platelet function analyzer) were
prolonged for both the collagen-epinephrine cartridge
(>300 seconds, reference range <170 seconds) and the
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collagen-adenosine diphosphate cartridge (>269 sec-
onds, reference range <120 seconds). Further studies
revealed a low FVIII:C (0.43 IU/ml, reference range
0.60–1.50 IU/ml) and VWF:Ag level (0.31 IU/ml, refer-
ence range 0.50–2.10 IU/ml). VWF:RCo was 0.09 IU/ml
(reference range 0.40–2.10 IU/ml), and VWF:CB was 0.10 IU/ml
(reference range 0.57–1.79 IU/ml). VWF:RCo/VWF:Ag ratio
was 0.29 (reference range>0.7), andRIPAvaluewas normal.'e
highest molecular weight VWF multimers were absent.
A diagnosis of VWD type 2A was made, but no genetic
mutation was identiAed by polymerase chain reaction
coupled with Sanger sequencing. A desmopressin (DDAVP)
infusion test was not done because of previous arrhythmias.
He did not use any anticoagulants.
Tranexamic acid and Haemate P had little e3ect on
bleeding symptoms and factor VIII activity. Because of
persistent hematuria, treatment consisting of 3,000 units of
Haemate P twice a day was started. Ninety minutes after in-
fusion of 3,000 units of Haemate P, FVIII:C was 0.53 IU/ml.
Higher doses of Haemate P (4,000 units, twice a day) were
required. Eventually, bleeding symptoms resolved. 'e clinical
suspicion of an AVWS was high, and mixing tests were done.
APTT on a plasma sample was measured before and after
incubation at 37°C for 120 minutes. However, no inhibitory
antibodies directed against VWF or factor VIII were detected.
A few months later, the patient complained of increased
rectal bleeding and daily epistaxis. Physical examination
showed slightly enlarged cervical, axillary, and inguinal lymph
nodes. FVIII:C was 0.07 IU/ml and VWF:Ag 0.22 IU/ml.
Again, mixing tests were performed, but no autoantibodies
were identiAed. A CTscan conArmed multiple enlarged lymph
nodes. A bone marrow biopsy was carried out. Multiple
nodular lesions composed of small atypical lymphoid cells with
irregular nuclei and micronucleoli were detected. Immuno-
histochemical study demonstrated that the lymphoid cells were
positive for CD5, CD20, CD79a, and cyclinD1 and negative for
CD3, CD138, and CD23. Fluorescence in situ hybridization
showed translocations of chromosome 11q13. Both surgeon
and radiologist were not able to biopsy a lymph node. Treatment
with R-CHOP chemoimmunotherapy resulted in a very good
partial response. A second bone marrow biopsy was done, and
only a few cyclin D1-positive cells were detected. A rapid dis-
appearance of the bleeding problems was observed. FVIII:C and
VWF:Ag completely normalized. Table 1 summarizes the exact
laboratory values before, during, and after therapy.
3. Discussion
AVWS is a rare hemorrhagic disorder. Multiple underlying
causes have been reported, mainly lymphoproliferative,
cardiovascular, myeloproliferative, and autoimmune dis-
orders and neoplasia [1, 2]. Our patient was diagnosed with
a mantle cell lymphoma, a rare subtype of B-cell non-Hodgkin
lymphoma.'e relationship betweenAVWS and non-Hodgkin
lymphoma has earlier been described in several case reports,
mainly in patients with a mucosa-associated lymphoid tissue
(MALT) lymphoma [3, 4]. To our best knowledge, the asso-
ciation between AVWS and mantle cell lymphoma was never
reported previously.
'e pathophysiology of AVWS is highly heterogeneous
and multifactorial. Several mechanisms have been reported
since the description of the Arst case of AVWS in 1968.
Frequently proposed mechanisms are development of spe-
ciAc or nonspeciAc autoantibodies directed against VWF,
adsorption of VWF by malignant cell clones, and increased
proteolytic degradation of VWF under conditions of high
shear stress. Rarely, synthesis of VWF is reduced, particu-
larly in patients with hypothyroidism [5].
In patients with lymphoproliferative disorders, AVWS is
mainly caused by the formation of autoantibodies directed
against VWF [5]. A functional defect of plasma VWF is
induced by binding of these speciAc inhibitors to functional
epitopes of VWF. Secondly, nonneutralizing autoantibodies
binding to nonfunctional domains of VWF can accelerate
the elimination of the large VWFmultimers from the circulation
by the formation of immune complexes [2, 5]. In our patient
diagnosed with amantle cell lymphoma, no inhibitory antibodies
were detected. Such a negative test result does, nevertheless, not
reject the diagnosis of AVWS.'e detection rate of inhibitors in
AVWS is low [1, 5]. Inhibitory activity against FVIII or VWFwas
conArmed by mixing tests in only 25% of patients with
AVWS associated with a lymphoproliferative disorder [2].
However, autoantibodies may still be present in the cir-
culation despite a negative test result [5]. Detection can be
prevented due to saturation of inhibitors in immune
complexes. Measurable functions of VWF will not be
inhibited when the clearance of VWF from the circulation
is increased by nonneutralizing autoantibodies. Enzyme-
linked immunosorbent assays (ELISAs) can be used to
detect these antibodies, but these assays are prone to false-
positive results due to the presence of ABO blood group
Table 1: Laboratory values before, during, and after therapy.
FVIII:C (IU/ml) VWF:Ag (IU/ml) VWF:RCo (IU/ml)
Normal values 0.60–1.50 0.50–2.10 0.40–2.10
Prechemotherapy 0.34 0.32 0.31
After R-CHOP cycle 1 0.60 0.51 n/a
After R-CHOP cycle 2 2.18 1.47 >1.00
After R-CHOP cycle 3 2.12 1.70 >1.00
After cytarabine + rituximab
(cycles 1 and 2) 2.18 1.94 n/a
Follow-up 2.32 2.03 >1.00
n/a: not available.
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antigens in immobilized plasma-derived VWF. Standard-
ized assays are not yet available [1, 5].
Furthermore, other pathogenic mechanisms may be
responsible for the occurrence of AVWS in our patient.
Selective adsorption of VWF onto malignant cells or other
cell surfaces has been described in patients with AVWS
associated with lymphomas. In a patient with a marginal
zone lymphoma and AVWS, Mow cytometry revealed that
the neoplastic lymphocytes strongly expressed platelet gly-
coprotein Ib and VWF [6].
Selective adsorption of the VWF protein by tumour cells
was also reported in patients with multiple myeloma [7],
Waldenstro¨m’s macroglobulinemia [8], and adrenal cortical
carcinoma [9].
Standard therapies for inherited VWD often have little
e3ect in patients with AVWS. Moreover, the bleeding phe-
notype of patients with AVWS associated with lymphoproli-
ferative disorders is generally more severe than in patients with
AVWS caused by other underlying diseases [5]. Symptomatic
treatment with for instance desmopressin, VWF-containing
concentrates, antiAbrinolytics, intravenous immunoglobulins,
or plasmapheresis can be initiated in case of acute bleeding
episodes [1]. Management of the underlying disorder can lead
to long-term remission of the acquired coagulopathy and
should therefore be considered whenever possible [1].
In the Netherlands, primary treatment for mantle cell
lymphoma consists of three courses of R-CHOP chemo-
immunotherapy and two courses of high-dose cytarabine
followed by autologous stem-cell transplantation. In our
patient, plasma levels of VWF:Ag improved gradually and
completely normalized after three cycles of chemotherapy.
Bleeding symptoms resolved completely.
Resolution of AVWS after initiation of therapy has in-
deed been described in several patients with a lymphoma
[3, 4]. However, a case of AVWS in a patient with a small
lymphocytic lymphoma illustrates that successful manage-
ment of the underlying condition not always results in re-
mission of the coagulopathy [10].
In conclusion, we described a rare case of a patient with
AVWS caused by a mantle cell lymphoma. Initiation of the
appropriate treatment with chemoimmunotherapy com-
pletely corrected the acquired coagulopathy. Because of
diDculties in the detection of autoantibodies and the fact
that di3erent mechanisms contribute to the pathogenesis of
AVWS, negative mixing studies do not reject the diagnosis
of AVWS. Suspicion of AVWS is raised by onset of bleeding
symptoms later in life and a negative bleeding history. A
thorough work-up to And the underlying cause is recom-
mended strongly.
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